U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Vaccines
  4. GARDASIL 9
  1. Vaccines

GARDASIL 9

STN:   125508
Proper Name: Human Papillomavirus 9-valent Vaccine, Recombinant
Tradename: GARDASIL 9
Manufacturer: Merck Sharp & Dohme LLC
Indications:

  • Indicated in girls and women 9 through 45 years of age for the prevention of the following diseases:
    • Cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58.
    • Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
  • And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:
    • Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma in situ (AIS).
    • Cervical intraepithelial neoplasia (CIN) grade 1.
    • Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3.
    • Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3.
    • Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.
  • Indicated in boys and men 9 through 45 years of age for the prevention of the following diseases:
    • Anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
    • Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
  • And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:
    • Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.

Product Information

Supporting Documents

Back to Top